Recruiting

Testing a new immune therapy combined with chemotherapy after melanoma surgery

Plain-English translation of NCT07400302 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a medication called , when combined with standard chemotherapy drugs, can help prevent mucosal melanoma from coming back after surgery. Mucosal melanoma is a rare but serious type of skin cancer. The study compares this new combination treatment to chemotherapy alone to see which approach works better.

Mucosal melanoma is aggressive and has high rates of recurrence even after surgery. New immune-boosting medications have shown promise in treating melanoma, but doctors need to know whether adding this medication to standard chemotherapy improves outcomes and is safe for patients with this specific type of cancer.

Do you qualify?

You likely qualify if…

you have been diagnosed with mucosal melanoma that has been completely surgically removed with clear margins
your tumor tissue shows a specific marker (PD-L1 positive) that makes it suitable for this treatment
you are at least 18 years old
your organs and bone marrow are functioning well enough to tolerate the treatment, confirmed by recent blood tests
you are willing to use effective contraception for 6 months after treatment ends if you could become pregnant or father a child
your surgery has fully healed and you can start treatment within 13 weeks after surgery

You likely don't qualify if…

you have previously received medications that boost the immune system (anti-PD-1 or anti-PD-L1/2 inhibitors)
you have untreated cancer that has spread to the brain, or your brain has not been clear of cancer for at least 4 weeks
you require ongoing use of immunosuppressant medications like prednisone
your blood counts, liver function, kidney function, or blood clotting ability are outside safe ranges

What participation looks like

You will receive either the new immune medication combined with chemotherapy drugs, or chemotherapy alone. The treatment will be given intravenously (through a vein) and you will need to visit the hospital or clinic regularly for treatment doses, blood tests, and checkups. The study involves 220 participants at multiple hospitals, and you will be randomly assigned to one of the two treatment groups. Throughout the study, your doctors will monitor you closely for how well the treatment works and any side effects you might experience.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

China

The first hospital of Jilin University, Changchun, Jilin